Verici Dx plc (AIM:VRCI)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Development of Prognostic and Diagnostic Tests for Kidney Transplant Patients	3.66M	3.34M	1.01M	-	-
Development of Prognostic and Diagnostic Tests for Kidney Transplant Patients Growth	9.73%	229.62%	-	-	-
Total	3.66M	3.34M	1.01M	-	-
Total Growth	9.73%	229.62%	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 8, 2026

Data Sources Report a data error